ovarian seromucinous carcinoma
ovarian seromucinous carcinoma
Explore linked clinical trials. Standard reference: MONDO:00040329 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | fallopian tube mucinous adenocarcinoma, ovarian seromucinous carcinoma | Active, not recruiting | Phase 2 | 2026-10-01 | NCT04739800 | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, ovarian seromucinous carcinoma | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT02839707 | |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT02502266 | |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube neoplasm, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian disorder, ovarian seromucinous carcinoma, ovarian serous tumor, ovarian transitional cell carcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02446600 | |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian carcinosarcoma, ovarian clear cell cystadenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, ovarian serous surface papillary adenocarcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 2 | 2026-09-10 | NCT02101775 | |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, malignant ovarian Brenner tumor, neoplasm, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-24 | NCT02068794 | |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, ovarian seromucinous carcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 1 | 2026-07-20 | NCT04092270 | |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian clear cell malignant adenofibroma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 3 | 2026-05-29 | NCT01167712 | |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, connective tissue neoplasm, cystic, mucinous, and serous neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, mucinous adenocarcinoma, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian clear cell malignant adenofibroma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated carcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 3 | 2025-12-30 | NCT00565851 |